"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 7 | 2 | 9 |
| 1997 | 15 | 1 | 16 |
| 1998 | 15 | 2 | 17 |
| 1999 | 11 | 2 | 13 |
| 2000 | 13 | 5 | 18 |
| 2001 | 9 | 4 | 13 |
| 2002 | 15 | 4 | 19 |
| 2003 | 18 | 5 | 23 |
| 2004 | 12 | 10 | 22 |
| 2005 | 29 | 8 | 37 |
| 2006 | 16 | 17 | 33 |
| 2007 | 16 | 22 | 38 |
| 2008 | 31 | 10 | 41 |
| 2009 | 24 | 22 | 46 |
| 2010 | 30 | 18 | 48 |
| 2011 | 37 | 19 | 56 |
| 2012 | 35 | 16 | 51 |
| 2013 | 42 | 22 | 64 |
| 2014 | 38 | 16 | 54 |
| 2015 | 50 | 32 | 82 |
| 2016 | 65 | 27 | 92 |
| 2017 | 47 | 18 | 65 |
| 2018 | 52 | 23 | 75 |
| 2019 | 50 | 17 | 67 |
| 2020 | 40 | 8 | 48 |
| 2021 | 55 | 16 | 71 |
| 2022 | 19 | 1 | 20 |
| 2023 | 25 | 3 | 28 |
| 2024 | 10 | 20 | 30 |
| 2025 | 41 | 9 | 50 |
| 2026 | 17 | 4 | 21 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models. Blood. 2026 Aug 06; 148(6):751-766.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. Mol Cancer Ther. 2026 Aug 04; 25(8):1342-1356.
-
Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group. Blood Adv. 2026 Jul 28; 10(14):4923-4930.
-
Time to Personalize Surveillance for Cancer Therapy-Related Cardiac Dysfunction in HER2-Targeted Therapy: One Size Does Not Fit All. Curr Heart Fail Rep. 2026 Jul 22; 23(1).
-
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. J Clin Oncol. 2026 Aug; 44(22):2140-2155.
-
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Circulation. 2026 Aug 04; 154(5):e188-e205.
-
Towards advancing cancer nanomedicine: Recent strategies for overcoming translational and toxicological challenges. Biomater Adv. 2026 Nov; 188:214987.
-
Synthesis, structure-activity relationships, antitumor activities and mechanistic studies of ENL-degrading compounds. Eur J Med Chem. 2026 Oct 15; 316:118989.
-
Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers. Cancer Med. 2026 Apr; 15(4):e71682.